THERAPEUTIC APPROACHES IN NEONATAL PERSISTENT PULMONARY HYPERTENSION

• Autor(a) principal: Jeyssa Alves Lima, Elaynne
• Data de Publicação: 2023
• Outros Autores: Cleia Rocha de Sousa, Joseane, Mônica Borges dos Santos, Márcia, dos Santos Resende, Marcilene, de Paula Barroso Lima Júnior, Francisco, Hilda Silva Soares, Ana, Gizelda Gomes Lages, Maria, Silva Costa, Iaciara, Dyeylly Ramos Torres Rios, Antonia, Jamil Oliveira, Átila, Chagas Monteiro, Danniele, Freitas de Sousa , Mirna, Leal Bonfim, Cinthya, Henrique Fiorin, Bruno, do Nascimento , Maraisa, Rodrigues Gomides, Rafael
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/797
• topic: Recém-nascido; Hipertensão Pulmonar Persistente Neonatal; Tratamento; Newborn; Neonatal Persistent Pulmonary Hypertension; Treatment; Recién nacido; Hipertensión Pulmonar Persistente Neonatal; Tratamiento

Objective: To evaluate the different therapeutic approaches available for the treatment of Persistent Pulmonary Hypertension of the Newborn (PPHN). Methodology: This is a wide-ranging literature review in which the research is based on the question "What are the therapeutic approaches for the treatment of neonatal persistent pulmonary hypertension?". The research was conducted in 2023 by consulting the Medical Literature Analysis and Retrievel System Online (MEDLINE) and Scientific Electronic Library Online (SciELO) databases. Results: Therapeutic approaches for the treatment of neonatal persistent pulmonary hypertension include the use of drugs such as milrinone and sildenafil, non-selective pulmonary vasodilators, inhaled nitric oxide when available, mechanical ventilation and the possibility of vasopressin in refractory cases. The choice of therapy depends on the severity of the condition and the resources available. Milrinone and sildenafil are common due to their vasodilator properties. Inhaled nitric oxide is preferred in severe cases, and mechanical ventilation plays a crucial role. Vasopressin may be an option in refractory cases, but its dose and safety are less well documented. Conclusion: PPHN is a challenging condition that requires a careful therapeutic approach. Based on the therapeutic options discussed in this study, it is clear that the choice should be guided by the severity of the patient, individual clinical characteristics and the availability of resources.